TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Manali Kamdar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.